| Name | Title | Contact Details |
|---|
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.
Esschem is the worlds most respected manufacturer of specialty acrylic polymers and monomers for medical and cosmetic uses.
Path-Tec is a leading provider of specimen collection kits and components. Our specialty is detailed specimen management. We understand the importance of specimen integrity so we work with laboratories to design kits that assist with proper specimen co...
Vascular Therapies, Inc., a privately-held late-stage biopharmaceutical company, is developing the Sirolimus-eluting collagen implant for local, perivascular drug delivery.
Kytopen is a biotechnology company that offers a customizable yet scalable multi-solution platform, which seamlessly links the discovery, development, and manufacturing phases of cell engineering. Their patent-pending technology, Flowfect®, enables tra...